Evidence map›Paper›PMID 37347278›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland.

Sara Colomer-Lahiguera, Claudia Canella, Stellio Giacomini, Kim Lê Van, Carla Pedrazzani, Matthias Naegele, Laure Thouvenin, Alix O'Meara Stern, Rosaria Condorelli, Tourane Corbière and 3 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Sara Colomer-LahigueraInstitute of Higher Education and Research & Department of Oncology Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Office 01/169 - PROLINE - Rte de la Corniche, 10-1010, Lausanne, Switzerland. sara.colomer-lahiguera@chuv.ch.ORCID https://orcid.org/0000-0003-2390-5198
Claudia CanellaInstitute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zürich, Switzerland.ORCID https://orcid.org/0000-0003-3152-6534
Stellio GiacominiInstitute of Higher Education and Research & Department of Oncology Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Office 01/169 - PROLINE - Rte de la Corniche, 10-1010, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-6972-5136
Kim Lê VanInstitute of Higher Education and Research & Department of Oncology Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Office 01/169 - PROLINE - Rte de la Corniche, 10-1010, Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-3439-4506
Carla PedrazzaniDepartment of Economics, Health and Social Sciences, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland.ORCID https://orcid.org/0000-0002-5059-3866
Matthias NaegeleCantonal Hospital St. Gallen, Department of Development and Quality Management in Nursing, Network Oncology, St. Gallen, Switzerland.ORCID https://orcid.org/0000-0003-3169-1812
Laure ThouveninDepartment of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.ORCID https://orcid.org/0000-0002-8578-7185
Alix O'Meara SternDepartment of Medical Oncology, Réseau Hospitalier Neuchatelois, Neuchâtel, Switzerland.
Rosaria CondorelliDepartment of Medical Oncology, EOC - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
Tourane CorbièreInstitute of Higher Education and Research & Department of Oncology Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Office 01/169 - PROLINE - Rte de la Corniche, 10-1010, Lausanne, Switzerland.
Claudia M WittInstitute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-5440-7805
Manuela EicherInstitute of Higher Education and Research & Department of Oncology Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Office 01/169 - PROLINE - Rte de la Corniche, 10-1010, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-7691-0719
Karin RibiDepartment Health, Kalaidos University of Applied Sciences, Zürich, Switzerland.ORCID https://orcid.org/0000-0003-4724-1197
University of Lausanne · CHUniversity of Zurich · CHHospital Neuchâtel · CHKalaidos University of Applied Sciences · CHUniversità della Svizzera italiana · CHUniversity Hospital of Geneva · CHUniversity of Applied Sciences and Arts of Southern Switzerland · CHUniversity of St.Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to describe the experience of Swiss oncological patients during the COVID-19 pandemic.

methodsA national multi-center study including five hospitals covering the three main language regions of Switzerland was conducted between March and July 2021. Patients with melanoma, breast, lung, or colon cancer receiving active systemic anti-cancer treatment at the time of the COVID-19 pandemic were included. We conducted semi-structured telephone or onsite interviews alongside the administration of distress and resilience-validated questionnaires. Thematic analysis was performed for the qualitative data and descriptive statistics for the quantitative data.

resultsSixty-two cancer patients with a mean age of 61 (SD=14) (58% female) were interviewed. Based on the interviews, we identified that the experience of having cancer during the COVID-19 pandemic was related to five dimensions: psychological, social, support, healthcare, and vaccination. Three themes transverse the five dimensions: (a) needs, (b) positive changes, and (c) phases of the pandemic. In general, patients did not experience delays or disruptions in their cancer treatment nor felt additionally burdened by the pandemic. Lockdown and isolation were reported as mixed experiences (positive and negative), and access to vaccination reassured patients against the risk of infection and instilled hope to return to normalcy. Additionally, we found low distress levels (M=2.9; SD=2.5) and high resilience scores (M=7; SD=1.3) in these patients.

conclusionSwiss patients with cancer did not express major needs or disruptions in their care during this period of the COVID-19 pandemic. Results identify the mixed experiences of patients and highlight the high resilience levels.

Indexed as

COVID-19NeoplasmsCommunicable Disease ControlFemaleHumansMaleMiddle AgedPandemicsPatient Reported Outcome MeasuresSwitzerlandCOVID-19DistressOncologyPatient-reported experienceResilience

Identifiers

PMID37347278
PMCPMC10287824
OpenAlexW4381598952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.